OnKure Therapeutics, Inc. (NASDAQ:OKUR) Given Consensus Rating of “Hold” by Analysts

Shares of OnKure Therapeutics, Inc. (NASDAQ:OKUR) have been assigned an average rating of “Hold” from the five analysts that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $32.00.

OKUR has been the subject of a number of recent research reports. Wall Street Zen upgraded shares of OnKure Therapeutics to a “sell” rating in a report on Saturday, November 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of OnKure Therapeutics in a research report on Monday, December 22nd.

OnKure Therapeutics Price Performance

NASDAQ:OKUR opened at $2.56 on Tuesday. The company has a market capitalization of $34.69 million, a price-to-earnings ratio of -0.53 and a beta of 0.46. The business has a 50 day moving average of $2.90 and a 200 day moving average of $2.79. OnKure Therapeutics has a 1-year low of $1.70 and a 1-year high of $6.18.

Institutional Investors Weigh In On OnKure Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. XTX Topco Ltd bought a new position in OnKure Therapeutics during the 2nd quarter worth approximately $25,000. Bailard Inc. purchased a new stake in shares of OnKure Therapeutics during the second quarter valued at approximately $34,000. Rangeley Capital LLC purchased a new stake in shares of OnKure Therapeutics during the second quarter valued at approximately $71,000. GSA Capital Partners LLP grew its holdings in shares of OnKure Therapeutics by 172.1% in the third quarter. GSA Capital Partners LLP now owns 59,224 shares of the company’s stock worth $163,000 after purchasing an additional 37,459 shares during the last quarter. Finally, Prosight Management LP increased its stake in shares of OnKure Therapeutics by 67.8% in the third quarter. Prosight Management LP now owns 267,959 shares of the company’s stock worth $737,000 after buying an additional 108,267 shares during the period. Institutional investors own 90.98% of the company’s stock.

About OnKure Therapeutics

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.